Drug Profile
Research programme: tuberculosis therapies - Sanofi
Alternative Names: TB therapies - Sanofi/Global Alliance for TB Drug Development (TB Alliance); TB therapies - Sanofi/Weill Cornell Medical CollegeLatest Information Update: 06 Aug 2018
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Global Alliance for TB Drug Development; Sanofi
- Class Tuberculosis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Tuberculosis
Most Recent Events
- 31 Jul 2018 Discontinued for Tuberculosis in USA (unspecified route)
- 04 Nov 2017 No recent reports of development identified for research development in Tuberculosis in USA
- 20 Sep 2012 Sanofi and Global Alliance for TB Drug Development entered a new collaborative agreement to accelerate discovery and development of new Tuberculosis therapies